Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

This study has been completed.
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00005823
First received: June 2, 2000
Last updated: December 17, 2013
Last verified: September 2006

June 2, 2000
December 17, 2013
December 1998
Not Provided
  • Survival [ Designated as safety issue: No ]
  • Response achievement [ Designated as safety issue: No ]
  • Response duration [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00005823 on ClinicalTrials.gov Archive Site
  • Toxicity by WHO Toxicity Grading after each treatment course [ Designated as safety issue: Yes ]
  • Quality of life EORTC QLQ-C30 at 3 days, 1 month, 3 months, and 6 months from study entry [ Designated as safety issue: No ]
  • Resource use (use of blood products, antibiotics and days in hospital) after each treatment course [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known if stronger doses of chemotherapy given over a longer period of time are as well tolerated or as effective as less intensive chemotherapy.

PURPOSE: This randomized phase III trial is studying intensive regimens of chemotherapy to see how well they work compared to nonintensive regimens of chemotherapy in treating older patients with acute myeloid leukemia or myelodysplastic syndrome.

OBJECTIVES:

  • Compare the response rate, survival, quality of life, and supportive care requirements with intensive versus nonintensive chemotherapy in older patients with acute myeloid leukemia or high risk myelodysplastic syndrome.
  • Compare response achievement, response duration, survival, toxicity and supportive care requirements with differing doses of daunorubicin and cytarabine in these patients receiving intensive chemotherapy.
  • Determine the efficacy of PSC 833 in enhancing the effects of daunorubicin in these patients receiving intensive chemotherapy.
  • Compare relapse rate, deaths in complete remission, disease free survival, and survival with short versus long intensive chemotherapy in these patients.
  • Compare response achievement, response duration, survival, toxicity, quality of life, and resource use with hydroxyurea versus cytarabine in these patients receiving low dose chemotherapy.
  • Determine response achievement, response duration, survival, toxicity, quality of life, and supportive care requirements with the addition of tretinoin to the nonintensive chemotherapy in these patients.
  • Assess the correlation between P-gp and BCL-2 in family members and treatment outcomes and other prognostic factors in these patients with these treatment regimens.

OUTLINE: This is a randomized, multicenter study. Patients are randomized or electively assigned to either intensive or nonintensive chemotherapy*.

Intensive chemotherapy

  • Induction therapy: Patients are randomized to 1 of 6 treatment arms. Patients receive 2 courses of chemotherapy comprising 1 of 2 daunorubicin doses, 1 of 2 cytarabine doses, thioguanine, and with or without PSC 833.

Patients receive daunorubicin IV once daily on days 1-3 with cytarabine IV twice daily and oral thioguanine once daily on days 1-10 during course 1. Treatment repeats in approximately 31 days as in course 1 except cytarabine and thioguanine are given only on days 1-8.

  • Arm I: Patients receive higher dose of daunorubicin, lower dose of cytarabine, and thioguanine.
  • Arm II: Patients receive higher dose of daunorubicin, higher dose of cytarabine, and thioguanine.
  • Arm III: Patients receive lower dose of daunorubicin, lower dose of cytarabine, and thioguanine.
  • Arm IV: Patients receive lower dose of daunorubicin, higher dose of cytarabine, and thioguanine.
  • Arm V: Patients receive treatment as in arm III in combination with continuous infusion of PSC 833 beginning day 1.
  • Arm VI: Patients receive treatment as in arm IV in combination with continuous infusion of PSC 833 beginning on day 1.

Patients with refractory disease after the first course of induction chemotherapy may continue with the intensive protocol arm or enter the nonintensive arm*. Patients who do not achieve complete remission after completion of induction chemotherapy are removed from study. Patients in complete remission after induction therapy receive consolidation therapy.

  • Consolidation therapy: Patients in complete remission after induction are randomized to either short or long consolidation.

    • Short consolidation: Patients receive mitoxantrone IV on days 1-3 and cytarabine IV over 2 hours twice daily on days 1-3.
    • Long consolidation: Patients complete short consolidation and then receive idarubicin IV over 5 minutes once daily on days 1 and 3, cytarabine IV over 2 hours twice daily and etoposide IV over 1 hour once daily on days 1-3.

Non-intensive chemotherapy*

  • Patients are randomized to 1 of 4 treatment arms.

    • Arm I: Patients receive oral hydroxyurea as necessary to control WBC count until treatment failure.
    • Arm II: Patients receive hydroxyurea as in arm I and oral tretinoin daily for up to 16 weeks.
    • Arm III: Patients receive low dose cytarabine subcutaneously twice daily on days 1-10 every 28 days for a minimum of 4 courses.
    • Arm IV: Patients receive cytarabine as in arm III plus oral tretinoin daily for up to 16 weeks.

NOTE: *Patients with liver function test > 2 times upper limit of normal are not eligible for nonintensive randomization

Quality of life is assessed at study entry, and then at 1, 3, and 6 months.

Patients are followed at one year.

PROJECTED ACCRUAL: Approximately 2,000 patients (1,200 to intensive arm and 800 to nonintensive arm) will be accrued for this study over 5 years.

Interventional
Phase 3
Allocation: Randomized
Primary Purpose: Treatment
  • Leukemia
  • Myelodysplastic Syndromes
  • Myelodysplastic/Myeloproliferative Neoplasms
  • Drug: cytarabine
  • Drug: daunorubicin hydrochloride
  • Drug: etoposide
  • Drug: hydroxyurea
  • Drug: idarubicin
  • Drug: mitoxantrone hydrochloride
  • Drug: thioguanine
  • Drug: tretinoin
  • Drug: valspodar
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
2000
December 2007
Not Provided

DISEASE CHARACTERISTICS:

  • Acute myeloid leukemia (de novo or secondary) OR
  • Myelodysplastic syndrome

    • More than 10% myeloblasts in the bone marrow
    • Refractory anemia with excess blasts
    • Refractory anemia with excess blasts in transformation
    • Chronic myelomonocytic leukemia
  • No acute promyelocytic leukemia (FAB type M3)
  • No blastic phase chronic myeloid leukemia

PATIENT CHARACTERISTICS:

Age:

  • 60 and over (younger patients allowed if intensive chemotherapy not indicated)

Performance status:

  • Not specified

Life expectancy:

  • Not specified

Hematopoietic:

  • Not specified

Hepatic:

  • No liver function test ≥ 2 times normal (for non-intensive therapy arm)

Renal:

  • Not specified

Cardiovascular:

  • No myocardial infarction within past 6 months in patients receiving daunorubicin or PSC 833

Other:

  • No other concurrent active malignancy

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • No prior cytotoxic chemotherapy for leukemia

Endocrine therapy:

  • Not specified

Radiotherapy:

  • Not specified

Surgery:

  • Not specified
Both
60 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT00005823
CDR0000067831, LRF-AML14, EU-20016, ISRCTN62207270
Not Provided
Not Provided
Leukemia Research Fund
Not Provided
Study Chair: Alan K. Burnett, MD, FRCP The University of New South Wales
National Cancer Institute (NCI)
September 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP